Globus Medical is a medical devices business based in the US. Globus Medical shares (GMED) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $72.46 – an increase of 0.76% over the previous week. Globus Medical employs 5,300 staff and has a trailing 12-month revenue of around $2.5 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $72.46 |
|---|---|
| 52-week range | $50.00 - $94.93 |
| 50-day moving average | $73.84 |
| 200-day moving average | $77.04 |
| Wall St. target price | $97.46 |
| PE ratio | 95.88 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.75 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $71.51 from 2025-05-07
| 1 week (2025-05-01) | 0.56% |
|---|---|
| 1 month (2025-04-09) | -3.73% |
| 3 months (2025-02-07) | -18.39% |
| 6 months (2024-11-08) | -11.59% |
| 1 year (2024-05-09) | 11.11% |
|---|---|
| 2 years (2023-05-08) | 22.93% |
| 3 years (2022-05-06) | 9.76% |
| 5 years (2020-05-08) | 44.44% |
Valuing Globus Medical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Globus Medical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Globus Medical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 96x. In other words, Globus Medical shares trade at around 96x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Globus Medical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9255. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Globus Medical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Globus Medical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $695 million.
The EBITDA is a measure of a Globus Medical's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.5 billion |
|---|---|
| Operating margin TTM | 18.95% |
| Gross profit TTM | $1.7 billion |
| Return on assets TTM | 5.33% |
| Return on equity TTM | 2.52% |
| Profit margin | 4.09% |
| Book value | $30.40 |
| Market Capitalization | $9.9 billion |
TTM: trailing 12 months
We're not expecting Globus Medical to pay a dividend over the next 12 months.
Over the last 12 months, Globus Medical's shares have ranged in value from as little as $50 up to $94.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Globus Medical's is 1.288. This would suggest that Globus Medical's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Globus Medical, Inc. , a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .